Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).
Osborne, J.D., Matthews, T.P., McHardy, T., Proisy, N., Cheung, K.M., Lainchbury, M., Brown, N., Walton, M.I., Eve, P.D., Boxall, K.J., Hayes, A., Henley, A.T., Valenti, M.R., De Haven Brandon, A.K., Box, G., Jamin, Y., Robinson, S.P., Westwood, I.M., van Montfort, R.L., Leonard, P.M., Lamers, M.B., Reader, J.C., Aherne, G.W., Raynaud, F.I., Eccles, S.A., Garrett, M.D., Collins, I.
J.Med.Chem.
